Bolder BioTechnology awarded NIH research grant
BOULDER — Bolder BioTechnology Inc., a Boulder-based protein therapy pharmaceutical firm, was recently awarded a $593,507 grant to study the use of the company’s therapies to treat radiation exposure.
The two-year grant is from the National Institute of Allergy and Infectious Diseases of The National Institutes of Health, according to a company news release.
The research project will be led by George Cox of Bolder BioTechnology and Christie Orschell of Indiana University School of Medicine.
SPONSORED CONTENT
Exploring & expressing grief
Support groups and events, as well as creative therapies and professional counseling, are all ways in which Pathways supports individuals dealing with grief and loss.
BOULDER — Bolder BioTechnology Inc., a Boulder-based protein therapy pharmaceutical firm, was recently awarded a $593,507 grant to study the use of the company’s therapies to treat radiation exposure.
The two-year grant is from the National Institute of Allergy and Infectious Diseases of The National Institutes of Health, according to a company news release.
The research project will be led by George Cox of Bolder BioTechnology and Christie Orschell of Indiana University School of Medicine.
…THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
